Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthon, Perrigo gain US FDA nod for generic allergy drug, winning first-to-file status

This article was originally published in Scrip

Executive Summary

Perrigo's shares got a slight 2.1% boost, or $1.80, on 18 May after its partner Synthon Pharmaceuticals won approval from the US FDA on their abbreviated new drug application (ANDA) for Levocetirizine solution, a generic version of UCB's Xyzal, a histamine H1-receptor antagonist indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis and as a treatment for uncomplicated skin manifestations of chronic idiopathic urticaria.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012977

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel